Doximity, Inc.

DOCS trades at a strikingly reasonable 19.3x earnings for a SaaS-adjacent healthcare software play, well below typical tech multiples despite solid positioning in a mission-critical vertical. The 11.52% short float suggests meaningful skepticism, yet RSI at 56.1 indicates the stock sits squarely in neutral territory—neither overbought nor oversold. Trading below its 52-week high with a $4.6B valuation leaves room for both upside surprises and disappointment. The combination of a moderate valuation multiple, subdued momentum, and non-trivial short interest hints at a stock caught between institutional conviction and structural skepticism, creating potential squeeze dynamics if execution accelerates or sentiment shifts unexpectedly.